<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01187290</url>
  </required_header>
  <id_info>
    <org_study_id>chest1001</org_study_id>
    <nct_id>NCT01187290</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy Versus Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases</brief_title>
  <official_title>Preoperative Chemoradiotherapy vs. Chemotherapy Alone in Nonsmall Cell Lung Cancer (NSCLC) Patients With Mediastinal Lymph Node Metastases (Stage IIIA, N2): A Randomized Prospective Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this trial is to compare feasibility and efficacy of sequential&#xD;
      neoadjuvant chemoradiotherapy with 44Gy concomitant boost to neoadjuvant chemotherapy alone.&#xD;
      Secondary objectives are to assess the value of position emission tomography (PET）in&#xD;
      predicting pathological response and event-free survival（EFS）in stage IIIA non-small cell&#xD;
      lung cancer (NSCLC). Further to compare the amount of serum DNA in patients with stage IIIa&#xD;
      NSCLC before, during and after chemotherapy, before and after radiotherapy (in arm A) and&#xD;
      during follow-up in patients randomized into the trial and to correlate the Deoxyribonucleic&#xD;
      acid (DNA) variation with tumor response, remission duration and overall survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operability</measure>
    <time_frame>within the first 30 days (plus or minus 3 days) after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative 30-day mortality</measure>
    <time_frame>30 days after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>30 days after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Chemotherapy Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel 75 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>neoadjuvant chemoradiotherapy</intervention_name>
    <description>Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks</description>
    <arm_group_label>neoadjuvant chemoradiotherapy</arm_group_label>
    <arm_group_label>neoadjuvant chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven NSCLC with nodal metastases: T1-3N2M0&#xD;
&#xD;
          -  Performance status 0-1&#xD;
&#xD;
          -  Patient medically fit enough for protocol therapy, including operability&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  No previous chemo- or radiotherapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with prior or concomitant malignancies Allowed are: non-melanomatous skin&#xD;
             cancer, adequately treated in situ cervical cancer or any other neoplastic diseases&#xD;
             with disease-free interval ³ 5 years.&#xD;
&#xD;
          -  Presence or history of any distant metastasis&#xD;
&#xD;
          -  Unstable cardiac disease requiring treatment, congestive heart failure or angina&#xD;
             pectoris even if medically controlled, significant arrhythmia, or prior history of&#xD;
             myocardial infarction in the last 3 months&#xD;
&#xD;
          -  History of significant neurologic or psychiatric disorders including psychotic&#xD;
             disorders, dementia or seizures that would prohibit the understanding and giving of&#xD;
             informed consent&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Gastric ulcers&#xD;
&#xD;
          -  Preexisting peripheral neuropathy (&gt; grade 1)&#xD;
&#xD;
          -  Other serious underlying medical condition which could impair the ability of the&#xD;
             patient to participate in the trial&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs&#xD;
&#xD;
          -  Pretreatment with any other cytostatic therapy&#xD;
&#xD;
          -  Previous radiotherapy to the chest&#xD;
&#xD;
          -  Concurrent treatment with prednisone (or equivalent) except: for the prophylactic&#xD;
             medication regimen before treatment, treatment of acute hypersensitivity reactions or&#xD;
             chronic treatment (initiated &gt; 6 months prior to trial entry) at low dose (£ 20 mg&#xD;
             methylprednisolone or equivalent)&#xD;
&#xD;
          -  Definite contraindications for the use of corticosteroids as premedication&#xD;
&#xD;
          -  Treatment within a clinical trial within 30 days prior to trial entry&#xD;
&#xD;
          -  Socioeconomic or geographic circumstances that may prohibit proper staging, treatment&#xD;
             or follow-up procedures&#xD;
&#xD;
          -  Pregnancy, lactation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>luo qingquan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai Chest Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luo qingquan, M.D</last_name>
    <phone>86-21-62821990</phone>
    <email>liziming1980@yahoo.com.cn</email>
  </overall_contact>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 19, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2010</study_first_posted>
  <last_update_submitted>August 23, 2010</last_update_submitted>
  <last_update_submitted_qc>August 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Luo qinquan</name_title>
    <organization>shanghai chest hospital</organization>
  </responsible_party>
  <keyword>Preoperative chemoradiotherapy</keyword>
  <keyword>stage IIIA, N2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lymphatic Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

